LRMN and Miltenyi Biotec meeting agenda
The March 2015 event will focus on CAR-T therapy
The LRMN's first meeting of 2015 will discuss cancer immunotherapy using T cells, with presentations by experts on the topic from the University of Pennsylvania, which had joined forces with Novartis, and Juno Therapeutics.
18.00: Registration over tea and coffee in the Gustave Tuck Lecture Theatre (Wilkins Building, UCL)
18.30: Welcome - Dr. Emily Culme-Seymour, LRMN (London, UK) and Jason Jones, Miltenyi Biotec (UK)
18.35: Engineering Targeted Immunity from Patient's Own Cells to Treat Untreatable Cancers - Professor Bruce Levine, Abramson Cancer Centre of the University of Pennsylvania (Philadelphia, PA, US)
19.15: Q & A
19.20: Juno's Approach to Cellular Immunotherapy - Hans Bishop, CEO & President, Juno Therapeutics (Seattle, WA, USA)
20.00: Q & A
20.05: Closing remarks - Prof. Chris Mason, Advanced Centre for Biochemical Engineering, UCL (London, UK) and Jason Jones, Miltenyi Biotec (UK)
20.10–22.00: LRMN Reception - Network whilst enjoying a glass of wine or two in the Haldane Room (Wilkins Building, UCL)
Are you attending this meeting? Let us know in the comments below!